Multidisciplinary cancer care

On this page

🤝 The Cancer Dream Team

  • Multidisciplinary Team (MDT) / Tumor Board: A collaborative group of specialists who jointly manage cancer patients, representing the modern standard of care.
  • Primary Goal: To develop a comprehensive, individualized treatment plan by reaching a consensus on diagnosis, staging, and the optimal sequence of therapies.

Multidisciplinary Tumor Board Discussing Patient Scans

  • Core Members (📌 SMRRP):
    • Surgical Oncologist: Manages surgical resection.
    • Medical Oncologist: Administers systemic therapy (chemo, immunotherapy).
    • Radiation Oncologist: Delivers local radiation therapy.
    • Radiologist: Interprets imaging for staging.
    • Pathologist: Provides tissue diagnosis & molecular profiling.
  • Key Ancillary Support: Palliative care, genetics, social work, nutrition, oncology nursing.

High-Yield: The MDT approach is strongly associated with improved survival, better adherence to evidence-based guidelines, and increased patient enrollment in clinical trials.

🤝 Management - The Tumor Board Huddle

A regularly scheduled meeting where a multidisciplinary team (MDT) discusses individual cancer cases to formulate a consensus treatment plan. It is the cornerstone of modern, patient-centered oncologic care.

  • Key Objectives:

    • Establish accurate diagnosis & staging.
    • Develop evidence-based, personalized treatment plans.
    • Improve inter-specialty communication & coordination.
    • Increase enrollment in clinical trials.
    • Ensure adherence to NCCN/ASCO guidelines.
  • Core Participants:

    • Surgical Oncologist
    • Medical Oncologist
    • Radiation Oncologist
    • Radiologist
    • Pathologist
    • Nurse Navigator / Coordinator
    • Palliative Care, Genetics, Social Work (as needed)

⭐ Multidisciplinary tumor board review can alter the diagnostic, staging, or treatment plan in 10-40% of cancer cases, significantly improving adherence to clinical guidelines and patient outcomes.

Tumor Board Workflow:

💡 The surgeon's input is crucial for determining resectability and the optimal sequence of surgery with neoadjuvant or adjuvant therapies.

🚧 Complications - Communication Breakdowns

  • Root Causes of Failure:
    • Lack of standardized handoffs (e.g., SBAR, I-PASS).
    • Information silos from non-integrated Electronic Health Records (EHRs).
    • Hierarchical culture discouraging junior members from speaking up.
    • Time constraints leading to rushed or incomplete exchanges.
    • Diffusion of responsibility ("bystander effect" in a clinical team).
  • Clinical & System Consequences:
    • ⚠️ Medical Errors: Medication mistakes, treatment delays, diagnostic inaccuracies.
    • Conflicting information given to patients, causing confusion and anxiety.
    • Fragmented care plans with poor execution and follow-up.
    • ↓ Patient satisfaction and ↑ provider burnout.

⭐ The Joint Commission estimates that communication failures are a root cause in over 70% of sentinel events (e.g., wrong-site surgery, unexpected death).

⚡ Biggest Takeaways

  • Multidisciplinary Teams (MDTs) or Tumor Boards are the standard of care for most cancers.
  • Core members: surgeons, medical/radiation oncologists, pathologists, radiologists.
  • Goal: Create a comprehensive, individualized treatment plan.
  • Improves patient outcomes, adherence to guidelines, and clinical trial enrollment.
  • Key decisions: accurate staging, assessing resectability, and sequencing therapies (neoadjuvant vs. adjuvant).
  • Promotes shared decision-making with the patient, improving care coordination.

Practice Questions: Multidisciplinary cancer care

Test your understanding with these related questions

A research team develops a new monoclonal antibody checkpoint inhibitor for advanced melanoma that has shown promise in animal studies as well as high efficacy and low toxicity in early phase human clinical trials. The research team would now like to compare this drug to existing standard of care immunotherapy for advanced melanoma. The research team decides to conduct a non-randomized study where the novel drug will be offered to patients who are deemed to be at risk for toxicity with the current standard of care immunotherapy, while patients without such risk factors will receive the standard treatment. Which of the following best describes the level of evidence that this study can offer?

1 of 5

Flashcards: Multidisciplinary cancer care

1/5

EF < _____% and MI within _____ months are absolute contraindications to non-cardiac surgery

TAP TO REVEAL ANSWER

EF < _____% and MI within _____ months are absolute contraindications to non-cardiac surgery

35

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial